As of 2025-05-16, the Relative Valuation of Eagle Pharmaceuticals Inc (EGRX) is 30.61 USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.14 USD, the upside of Eagle Pharmaceuticals Inc based on Relative Valuation is 1330.3%.
The range of the Relative Valuation is 19.06 - 48.93 USD.
| Range | Selected | |
| Trailing P/E multiples | 20.5x - 25.4x | 24.6x |
| Forward P/E multiples | 18.2x - 25.4x | 19.9x |
| Fair Price | 19.06 - 48.93 | 30.61 |
| Upside | 790.6% - 2186.4% | 1330.3% |
| Date | P/E |
| 2025-05-13 | 2.11 |
| 2025-05-12 | 2.14 |
| 2025-05-09 | 2.14 |
| 2025-05-08 | 2.04 |
| 2025-05-07 | 2.04 |
| 2025-05-06 | 2.04 |
| 2025-05-05 | 2.11 |
| 2025-05-02 | 2.11 |
| 2025-04-30 | 2.10 |
| 2025-04-29 | 2.10 |
| 2025-04-28 | 2.06 |
| 2025-04-25 | 1.83 |
| 2025-04-24 | 1.61 |
| 2025-04-23 | 2.11 |
| 2025-04-22 | 1.77 |
| 2025-04-17 | 1.93 |
| 2025-04-16 | 1.74 |
| 2025-04-15 | 1.93 |
| 2025-04-14 | 1.34 |
| 2025-04-11 | 1.29 |
| 2025-04-10 | 1.07 |
| 2025-04-09 | 1.50 |
| 2025-04-08 | 1.61 |
| 2025-04-07 | 1.99 |
| 2025-04-04 | 2.02 |
| 2025-04-03 | 1.82 |
| 2025-04-02 | 1.66 |
| 2025-04-01 | 1.66 |
| 2025-03-31 | 1.05 |
| 2025-03-28 | 0.94 |
| 2025-03-27 | 1.01 |
| 2025-03-26 | 1.07 |
| 2025-03-25 | 1.23 |
| 2025-03-24 | 1.56 |
| 2025-03-21 | 1.60 |
| 2025-03-20 | 1.50 |
| 2025-03-19 | 1.34 |
| 2025-03-18 | 1.40 |
| 2025-03-17 | 1.61 |
| 2025-03-14 | 1.40 |
| 2025-03-13 | 1.40 |
| 2025-03-12 | 1.40 |
| 2025-03-11 | 1.11 |
| 2025-03-10 | 1.18 |
| 2025-03-07 | 0.91 |
| 2025-03-06 | 1.14 |
| 2025-03-05 | 1.25 |
| 2025-03-04 | 1.26 |
| 2025-03-03 | 1.29 |
| 2025-02-28 | 1.29 |